The Sanguine Difference

By simplifying the patient donation process, we have built a highly-engaged group of donors for minimally-invasive biospecimens.

Our Success In Numbers

2000+

Studies
Completed

15,000+

Home Visits Completed

25+

Top Pharma
Clients

100+

Nonprofit Organization Partnerships

70,000+

Patient Member Community

How the Legacy Indirect Model Stacks Up Against Ours

 

   

  • Patient Access
  • Patient Centricity
  • Strategies for reach, recruitment, retention
  • Diversity of participant pool including hard-to-reach populations
  • Study participant recontact ability
  • Patient Community Access
  • Panoramic, long-term view of study participants
  • Clinically Relevant Specimen + Data
  • Biospecimen procurement
  • Sample integrity
  • Biospecimen and data owner
  • Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
  • Longitudinal sampling
  • Simultaneous collection of multiple biospecimen types
  • Large volume blood specimen collection (≤180 mL)
  • Patient-reported outcomes data
  • Same-day sample collection and delivery
  • Renewable medical record-derived data

Us
Direct Patient Access

  • Patient Access
  • Patient Centricity Engaged homegrown communities
  • Strategies for reach, recruitment, retention Mobile, virtual, flexible
  • Diversity of participant pool including hard-to-reach populations Unlimited by geographic reach and access to medical facility
  • Study participant recontact ability In-home
  • Patient Community Access Broad, multi-faceted
  • Panoramic, long-term view of study participants High retention, amendable study design, 95% patient retention rate
  • Clinically Relevant Specimen + Data
  • Biospecimen procurement Yes
  • Sample integrity Yes
  • Biospecimen and data owner Yes
  • Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
    Yes
  • Longitudinal sampling
         Yes
  • Simultaneous collection of multiple biospecimen types Yes
  • Large volume blood specimen collection (≤180 mL) Yes
  • Patient-reported outcomes data Yes
  • Same-day sample collection and delivery Yes
  • Renewable medical record-derived data Yes

Biobanks
Indirect Patient Access

  • Patient Access
  • Patient Centricity Third-party mediated, transactional
  • Strategies for reach, recruitment, retention Confined, brick and mortar
  • Diversity of participant pool including hard-to-reach populations Limited by geographic reach and access to medical facility
  • Study participant recontact ability Clinical collection center
  • Patient Community Access Oncology specialized
  • Panoramic, long-term view of study participants Low to no patient retention
  • Clinically Relevant Specimen + Data
  • Biospecimen procurement No
  • Sample integrity No
  • Biospecimen and data owner No
  • Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
    No
  • Longitudinal sampling
         No
  • Simultaneous collection of multiple biospecimen types No
  • Large volume blood specimen collection (≤180 mL) No
  • Patient-reported outcomes data No
  • Same-day sample collection and delivery No
  • Renewable medical record-derived data No
Young chemist working in the lab

Access challenging, hard-to-collect samples

Sanguine's unique patient-centric approach to biospecimen collection gives researchers access to rare patient populations and complex study designs such as event-based collection, longitudinal collections, and more.

Are you a researcher?

Find out how Sanguine can accelerate your study.

Request a Quote